Resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Journal of Thoracic Oncology

Volumn 4, Issue 11 SUPPL. 3, 2009, Pages

  Wozniak, Antoinette J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; PF 299804; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 73549092487     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000361760.11575.54     Document Type: Conference Paper

References (10)

1. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042.
2. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809 -1818.
3. Mok T. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC). Presented at the European Society of Medical Oncology meeting, Stockholm, 2008. Abstract LBA2.
4. Camidge DR, Kabbinavar F, Martins R, et al. EGFR biomarker-selected randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naïve advanced NSCLC. J Thorac Oncol 2008;3:S268.
5. Hirsch FR, Dziadziuszko R, Camidge DR, et al. Biomarker status correlates with clinical benefit: phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected NSCLC population. J Thorac Oncol 2008;3:S267.
6. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3352-3357.
7. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:3.
8. Khambata-Ford S. K-Ras mutations and EGFR-related markers as potential predictors of cetuximab benefit in first line advanced NSCLC: results from the BMS 099 study. Presented at Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, 2008.
9. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377.
10. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.